Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL


Determination of Recommended Phase II Dose of Venetoclax (ABT-199) and Rituximab for Relapsed/Refractory CLL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (1/8/15)
Roberts AW et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ASH 2014;Abstract 325.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.